Status:
COMPLETED
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
Lead Sponsor:
Medtronic Diabetes
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
12-80 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared t...
Detailed Description
Glycemic control remains a significant challenge for both adult and adolescent Type 1 diabetics. Continuous Glucose Monitoring (CGMS) is currently used by clinicians to record continuous, retrospectiv...
Eligibility Criteria
Inclusion
- Age 12 - 80 years
- Type 1 Diabetes Mellitus diagnosed at least 1 year ago
- Using insulin infusion pump for past 6 months minimum
- Performing minimum 4 blood glucose tests per day
- Agree to treat to A1c targets
- Read and understand English
Exclusion
- Pregnant or planning pregnancy
- History of unresolved tape allergy or skin conditions
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT00211510
Start Date
June 1 2005
End Date
February 1 2007
Last Update
June 12 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Los Angeles
Los Angeles, California, United States, 90027
2
Stanford University
Stanford, California, United States, 94305
3
Atlanta Diabetes Associates
Atlanta, Georgia, United States, 30309
4
Joslin Diabetes Center
Boston, Massachusetts, United States, 02215